For parenteral sustained-release microspheres, PURASORB PDL 04A acid-terminated DL-lactide copolymer with an inherent viscosity of 0.4 dL/g in chloroform at 25°C is selected when a low-viscosity organic phase and rapid solvent extraction are required. A dispersed phase is prepared with polymer concentrations of 10–25% w/v in dichloromethane or in a 75:25 v/v dichloromethane–ethyl acetate mixture. Drug-to-polymer mass ratios are bracketed between 1:5 and 1:20 during formulation screening; exact loading is adjusted for particle-size distribution and release duration. The continuous phase is aqueous polyvinyl alcohol at 0.5–1.0% w/v prepared in demineralized water. Primary emulsification is performed in a rotor-stator mixer such as a Silverson L5M-A fitted with a square-hole high-shear screen at 3,000–8,000 rpm. The primary emulsion is transferred to a stirred hardening vessel containing 1–4 volumes of aqueous extraction medium at 20–25°C. Solvent removal is continued for 4–16 h under controlled agitation to obtain discrete spheres with a target Dv90 below 250 μm for injectability through needles of 19–21 G. Residual solvent levels must satisfy ICH Q3C(R8) options; for dichloromethane the parenteral concentration limit is 600 ppm. The resulting microspheres are vacuum-dried or lyophilized and packaged as a sterile powder for reconstitution. Compliance testing includes USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter in injections, and ISO 10993-5:2009 in vitro cytotoxicity.

Acid termination influences the internal microclimate during hydrolytic degradation. Carboxylic acid end groups can accelerate ester bond hydrolysis and lower local pH within the polymer matrix. For acid-sensitive peptides or nucleic acids, this characteristic requires formulation intervention with sparingly soluble buffering salts, co-encapsulation of weakly basic excipients, or reduced drug load. Particle porosity is controlled by the ratio of dichloromethane to ethyl acetate and by the rate of solvent removal. A higher ethyl acetate fraction lowers interfacial tension and modifies pore formation. Batch-to-batch variance is commonly observed in particle size and residual solvent; laser diffraction under ISO 13320:2020 and gas chromatography with headspace sampling are used for release. The acid-terminated grade is therefore more suited to neutral or base-stable actives that do not require near-neutral pH maintenance during long-term release. Finished lyophilized microspheres are intended for intramuscular or subcutaneous depot injection; published release-profile data for this specific configuration is limited.

What Limits Burst Release in NMP-Based Depot Formulations?

The injectable depot is formed by phase inversion when a polymer solution in N-methyl-2-pyrrolidone or dimethyl sulfoxide contacts an aqueous physiological environment. The polymer, drug, and solvent are compounded as a liquid fill for a pre-filled syringe or vial. Polymer concentrations of 20–50% w/w produce solutions with viscosities that balance syringeability and precipitation rate. At low polymer concentrations near 20% w/w, burst release rises because the precipitation front lags behind solvent efflux and dissolved drug is expelled before a continuous polymer skin forms. At polymer concentrations above 50% w/w, the depot forms rapidly, but injection force through gauges finer than 21 G can become a processing constraint. Co-solvents such as polyethylene glycol 400 or triacetin are used at 5–20% w/w to modify solvent exchange without fully dissolving the depot. The carboxylic acid end groups of PDL 04A increase water uptake relative to ester-terminated analogues, promoting autocatalytic hydrolysis after implant formation. Terminal finished product is a sterile liquid formulation in a pre-filled syringe that solidifies into a subcutaneous or intramuscular depot upon contact with tissue fluid. Compounding is performed under vacuum to remove dissolved gas, and the solution is filled aseptically because terminal moist-heat sterilization of the polymer solution may reduce inherent viscosity.

The acid-terminated DL-lactide copolymer is more hydrophilic than ester-terminated forms of similar molecular weight. This property stabilizes early water ingress during phase inversion, but it also narrows the working window between depot solidification and rapid polymer hydration. Syringeability data on production filling lines show that dissolved gas, poorly controlled polymer concentration, and residual moisture shift the ejection force non-linearly. Pre-drying of the polymer at 40°C under vacuum until the pooled residual moisture is below 0.1% w/w is imposed where acid-sensitive actives are present. The depot formulation is not terminally filtered through 0.22 μm membranes at room temperature unless the polymer content is reduced below 15% w/w; higher concentrations require pre-sterilization of the polymer by gamma irradiation under controlled dose. Accelerated stability studies according to ISO 10993-6:2016 and cumulative release under USP <711> dissolution apparatus are required because the acid end groups can accelerate molecular weight loss in the hydrated state.

Nanoprecipitation of an acid-terminated DL-lactide copolymer is used when particle size must remain below 500 nm for intravenous compatibility or sterile filtration with 0.22 μm membranes. A water-miscible organic solvent such as acetone or acetonitrile dissolves the polymer at 1–10 mg/mL. This organic phase is added dropwise to an aqueous non-solvent phase containing a stabilizer, typically poloxamer 188 at 0.1–1.0% w/v, under controlled stirring. The solvent is removed by rotary evaporation at reduced pressure or by tangential flow filtration through regenerated cellulose membranes with a molecular weight cutoff of 100 kDa. Particle-size distribution is measured by dynamic light scattering under ISO 22412:2017, and zeta potential is determined by electrophoretic light scattering under ISO 13099-1:2012. Carboxylic acid end groups contribute negative surface charge at physiological pH; colloidal stability is monitored during scale-up because small shifts in pH or ionic strength alter aggregation kinetics. The terminal finished product is a lyophilized nanoparticle cake intended for reconstitution into sterile water or isotonic buffer. Compliance testing includes USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter in injections, and ICH Q3C(R8) residual solvent limits for acetone and acetonitrile.

Batch reproducibility in nanoprecipitation is more sensitive to mixing geometry than is commonly observed in microsphere manufacture. The ratio of solvent to anti-solvent, the injection rate, and the stabilizer concentration determine primary particle size and polydispersity. Flash nanoprecipitation in a confined impingement jet mixer produces narrower distributions than dropwise addition at pilot scale. Residual organic solvent must be reduced below pharmacopeial limits before lyophilization; residual acetone and acetonitrile are Class 3 solvents under ICH Q3C(R8) with high permitted daily exposures, but excess levels depress glass transition and destabilize the cake. Cryoprotectants such as trehalose or sucrose at 2–10% w/v are added before freeze-drying to prevent particle aggregation during reconstitution. The acid-terminated polymer is less suitable for cationic drugs that bind strongly to carboxylate surface groups and reduce zeta potential. Published data for this specific configuration is limited; therefore, the extent of drug-polymer electrostatic interaction should be evaluated case-by-case.

When Low-Viscosity Melt Grades Are Blended with Vinylpyrrolidone Copolymers

At processing temperatures above the glass transition, the 0.4 dL/g amorphous DL-lactide copolymer contributes melt fragility and reduced extruder torque when compounded with vinylpyrrolidone-based carriers for amorphous solid dispersions. A typical hot-melt extrusion run uses a co-rotating twin-screw extruder with an L/D ratio of 40:1, barrel zones set between 90°C and 160°C, and screw speeds of 50–200 rpm. The polymer is pre-blended at 10–30% w/w with copovidone or hypromellose acetate succinate and a low-dose active pharmaceutical ingredient. The low melt viscosity of this acid-terminated grade lowers the required barrel temperature, which is useful for thermally labile actives. However, carboxylic acid end groups can catalyze drug degradation at elevated temperature; pre-extrusion compatibility studies by differential scanning calorimetry and hot-stage microscopy are mandatory. Residual moisture is controlled by drying the blend at 40°C under vacuum for 12–24 h to a target moisture content below 0.1% w/w. Extruded strands are cooled on a stainless steel conveyor, pelletized, milled, blended with tableting excipients, and compressed into tablets or filled into capsules. Compliance includes USP <711> dissolution testing, USP <921> water determination, and ICH Q3C(R8) for any residual monomers or processing solvents.

The terminal finished product is an oral solid dosage form containing the drug dispersed in a polymeric matrix. The molecular weight of the DL-lactide copolymer is measured before and after extrusion by size-exclusion chromatography; an inherent-viscosity drop greater than 10% relative to input is typically investigated as a process excursion. The amorphous polymer does not provide crystalline reinforcement, and its low glass transition near 50–55°C may require storage below 25°C in low-humidity packaging. Processing boundaries include screw-temperature overshoot, poor feed zone feeding due to static charge, and torque fluctuations caused by inhomogeneous blend moisture. The acid-terminated grade is therefore selected for moderate oral release applications rather than implants that demand long-term mechanical load-bearing.

An amorphous DL-lactide copolymer with inherent viscosity 0.4 dL/g can be deposited as a thin resorbable film on stainless steel, nitinol, or polyether ether ketone implant surfaces by ultrasonic spray coating. The coating solution is prepared in ethyl acetate or acetone at 0.5–5.0% w/v polymer. The low solution viscosity of this grade allows fine droplet formation from an ultrasonic nozzle and layer-by-layer film growth without nozzle blockage. Substrate temperature is maintained between 35°C and 50°C to promote solvent evaporation without polymer dewetting. Surface preparation includes degreasing, plasma treatment, and where required silane coupling to improve interfacial adhesion. Film thickness is built by controlling flow rate, nozzle speed, and number of passes; single-pass thickness is typically kept below 5 μm to avoid pinhole formation. Post-deposition annealing at 60–80°C for 30–120 min densifies the film above its glass transition and reduces residual solvent. The terminal finished product is a coated implant, cannula, or catheter surface with a resorbable drug-eluting layer. Compliance testing includes ISO 10993-4:2017 hemocompatibility for blood-contact devices, ISO 10993-6:2016 local tissue response, ISO 10993-10:2021 irritation and sensitization, and ASTM F1635-16 hydrolytic degradation profiling.

This coating route is not suitable for load-bearing surfaces because the amorphous polyester film has low scratch resistance and cannot replace crystalline poly(L-lactide) under mechanical stress. Acid termination accelerates hydration at the coating surface, which may reduce pH in the boundary layer and accelerate degradation of incorporated acid-labile drugs. Inspection by scanning electron microscopy is used to detect cracking, delamination, and thickness non-uniformity. Coating mass per device is confirmed gravimetrically or by dissolution recovery; thickness may be measured by contact profilometry or spectroscopic ellipsometry. The process window narrows as ambient relative humidity exceeds 60%, at which point pre-drying of substrate and polymer becomes critical for film clarity. Final residual solvent limits follow ICH Q3C(R8) Option 2 for ethyl acetate and acetone, both Class 3 solvents. Published data for this specific grade in implant coating configurations is limited; coated-device performance must be qualified on production-representative substrates.

Bioresorbable Scaffold Fabrication by Solvent Casting and Porogen Leaching

Scaffold manufacture with a low-viscosity acid-terminated polymer begins by dissolving the polymer in chloroform at 5–15% w/v and dispersing a porogen such as sodium chloride or sucrose with particle-size fractions of 100–300 μm. The slurry is cast into stainless steel or PTFE molds and dried under a controlled solvent atmosphere to prevent skin formation. Porogen is leached in deionized water at 25–40°C for 24–72 h, with water changes every 8–12 h. The resulting porous structure is vacuum-dried to a residual moisture content below 0.5% w/w and packaged in foil under nitrogen. Carboxylic acid end groups increase surface hydrophilicity, which modifies protein adsorption and water uptake in tissue engineering applications. Pore volume and interconnectivity are assessed by mercury porosimetry or micro-computed tomography. Compressive properties may be measured according to ISO 604:2002 for plastics, with the understanding that the amorphous polymer will yield at low stress. The terminal finished product is a resorbable porous scaffold for cell ingrowth, not a load-bearing fixation device. Compliance testing includes ISO 10993-5:2009 in vitro cytotoxicity, ISO 10993-6:2016 local implantation response, and ASTM F1635-16 for hydrolytic degradation under simulated physiological conditions.

Residual chloroform must be controlled below the ICH Q3C(R8) Option 2 parenteral concentration limit of 60 ppm because the scaffold is intended for implantation. The solvent-casting step creates a density gradient if evaporation is too rapid; closed-chamber drying with slow vapor exchange reduces dense surface skin. The porogen size fraction controls pore geometry, while the polymer concentration controls wall thickness and mechanical integrity. The acid-terminated DL-lactide copolymer degrades faster than high-molecular-weight crystalline poly(L-lactide) and is suited to short-term scaffolds in which structural support is required for weeks rather than months. Hydrated scaffolds should be used in systems where acidic degradation products from low-pH microenvironments are physiologically tolerable. Published degradation kinetics for this specific configuration are limited; scaffold morphology must be characterized after each leaching and drying cycle to confirm interconnected porosity prior to terminal sterilization.